SORT1 1p13.3 locus

The 1p13.3 Locus — A Genetic LDL-Cholesterol Thermostat

Your chromosomes contain regulatory switches that control how much cholesterol
circulates in your blood. At position 1p13.3 on chromosome 1, a single-letter
DNA change creates or destroys a binding site for a protein called C/EBP |
CCAAT/enhancer binding protein, a transcription factor that regulates gene
expression, fundamentally altering
your liver's cholesterol management system.

This variant, rs12740374, sits in the 3' untranslated region of the CELSR2 gene
but controls expression of SORT1, which encodes sortilin | a cellular trafficking
receptor that directs proteins to different destinations within cells.
When the T allele is present, it creates a functional C/EBP binding site that
increases sortilin production in liver cells by more than 12-fold | compared to
the major G allele. This isn't a
subtle effect — it's one of the strongest genetic regulators of LDL cholesterol
discovered through genome-wide studies.

The Mechanism

Sortilin acts as an intracellular sorting receptor in hepatocytes, binding to
apolipoprotein B-100 (apoB) in the Golgi apparatus. When sortilin levels are
high (T allele carriers), it captures apoB-containing particles and routes them
to lysosomes for degradation | rather than allowing them to be secreted as VLDL
particles, reducing the amount of
VLDL that leaves the liver. Since VLDL particles are converted to LDL in
circulation, less VLDL secretion means lower plasma LDL cholesterol.

The molecular switch works like this: the T allele creates a perfect C/EBP
consensus binding site, while the G allele disrupts it. When C/EBP binds to the
T allele sequence, it increases SORT1 transcription. Reporter assays show
~4-fold greater gene activity | with the T allele compared to G in laboratory
experiments.

Importantly, sortilin's effect is context-dependent. It restricts apoB secretion
specifically under conditions of lipid loading and endoplasmic reticulum stress |
metabolic conditions common after high-fat meals,
but has minimal effect under basal conditions. This suggests the variant may be
particularly important during metabolic challenges.

Beyond reducing VLDL secretion, increased hepatic sortilin also enhances LDL
catabolism | the breakdown and clearance of LDL particles from the blood,
working through two complementary mechanisms to lower circulating LDL cholesterol.

The Evidence

The 1p13.3 locus ranks among the most robustly replicated genetic associations in
cardiovascular disease. Genome-wide association studies | meta-analyses combining
hundreds of thousands of individuals
consistently identify rs12740374 and its tightly linked neighbors (rs646776,
rs599839) as major LDL-cholesterol regulators.

Effect sizes are clinically meaningful. Each copy of the T allele (the
higher-sortilin, protective allele) lowers LDL cholesterol by approximately
0.18-0.19 mmol/L (7-7.5 mg/dL) | observed in both European Americans and African
Americans in the ARIC Study. Other
studies report reductions of 5-11 mg/dL per T allele | effect size varies by
ancestry, with Mexican Americans showing ~11 mg/dL reduction.

The cardiovascular benefit is substantial. Homozygosity for the protective T
allele is associated with a 40% reduction in myocardial infarction risk |
compared to GG homozygotes,
with odds ratios in the 0.51 range for coronary stenosis. The effect is mediated
primarily through LDL-cholesterol lowering, though the variant also reduces
protein C levels | a coagulation factor, suggesting a novel link between
lipoprotein metabolism and hemostasis.

Effect sizes are considerably larger in younger populations | 2.5-4.1% of LDL-C
variation in children and young adults, versus 1% in older subjects,
suggesting early-life effects may be particularly important for lifelong
cardiovascular risk.

Functional studies in mice confirm the mechanism. Sort1 knockout mice show
reduced lipoprotein secretion and protection from hypercholesterolemia | when
crossed with LDL receptor-deficient mice,
while sortilin overexpression increases plasma LDL levels. RNA interference
studies in human hepatocytes demonstrate that silencing SORT1 reduces apoB
secretion.

A pharmacogenetic meta-analysis | of statin response studies
found that rs12740374 is associated with an additional 1.5% increase per T
allele in LDL-C lowering when treated with statins, suggesting the variant may
predict drug response.

Practical Actions

If you carry one or two copies of the protective T allele, you start with a
genetic advantage for cholesterol management. Your liver naturally produces more
sortilin, routing more apoB to degradation and secreting less VLDL. This doesn't
mean you're immune to high cholesterol — diet, exercise, and other genetic
factors still matter — but you have a lower baseline risk.

For GG homozygotes, the opposite applies: less sortilin means more efficient VLDL
secretion and higher baseline LDL-cholesterol. This genetic predisposition makes
lifestyle modifications particularly important | dietary interventions that
reduce LDL-C are especially valuable when genetic factors work against you.

Dietary fiber and plant sterols work through complementary mechanisms. Soluble
fiber | 5-10 grams daily from oats, barley, psyllium, beans, and vegetables
reduces intestinal cholesterol absorption. Plant sterols/stanols | 2 grams daily
from fortified foods or supplements
compete with cholesterol for absorption, lowering LDL-C by 5-15%. A dietary
portfolio combining these approaches can reduce LDL-C by ~30%, rivaling
first-line statin therapy.

Since sortilin's effects are amplified under conditions of lipid loading and ER
stress | high-fat meals and metabolic stress,
GG carriers may see particular benefit from moderating saturated fat intake.
Studies show saturated fatty acids activate ERK signaling and suppress Sort1
expression | in obese and diabetic mice,
potentially worsening the GG genotype's baseline disadvantage.

Interactions

The 1p13.3 locus is part of a broader polygenic architecture of LDL cholesterol.
Variants in APOE, LDLR, PCSK9, APOB, and HMGCR | other major cholesterol-regulating
genes combine
additively to determine overall cholesterol levels and cardiovascular risk.
Genetic risk scores incorporating these loci predict familial hypercholesterolemia
in patients without monogenic mutations.

The nearby variants rs646776 and rs599839 are in near-perfect linkage
disequilibrium with rs12740374 | r² > 0.98, meaning they're almost always
inherited together and
represent the same biological signal. Other SNPs in this haplotype block include
rs629301, rs1277930, and rs583104.

Gene-diet interactions have been observed. While the locus primarily affects
baseline LDL-cholesterol, dietary interventions still work: carriers of the
higher-risk G allele respond normally to soluble fiber, plant sterols, and
Mediterranean dietary patterns | these interventions lower LDL-C regardless of
genotype.

Statin pharmacogenetics show that rs12740374 predicts treatment response, with T
allele carriers achieving slightly greater LDL-C reduction | an additional 1.5%
per allele on statin therapy.
This suggests that genetic testing could help predict who will achieve guideline
LDL-C targets on first-line therapy versus requiring combination treatment.

Gene-Gene Interaction Proposals

SORT1 × APOE (rs12740374 × rs429358/rs7412): APOE genotype determines LDL
receptor affinity, while SORT1 controls hepatic VLDL secretion. The combination
of SORT1 GG (high VLDL secretion) with APOE ε4/ε4 (impaired LDL clearance) may
create a compound risk state requiring aggressive dietary or pharmacologic
intervention. Conversely, SORT1 TT × APOE ε2/ε2 might confer exceptional
protection. Evidence: both loci are included in polygenic risk scores for
hypercholesterolemia | and show additive effects.

SORT1 × PCSK9 (rs12740374 × rs11591147): PCSK9 degrades LDL receptors, while
sortilin controls VLDL production and facilitates PCSK9 secretion | SORT1
enhances PCSK9 secretion from hepatocytes.
SORT1 GG (low sortilin) with PCSK9 gain-of-function variants may compound LDL-C
elevation through both increased production and reduced clearance. Evidence:
PCSK9 and LDLR show documented interaction effects | on statin response.